- Home
- JYD vs SNSE Comparison
JYD vs SNSE Comparison
Compare JYD & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | SNSE |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 10.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JYD | SNSE |
|---|---|---|
| Price | $4.20 | $9.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 77.8K | ★ 79.9K |
| Earning Date | 12-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,305,742.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.71 | $5.00 |
| 52 Week High | $400.00 | $18.35 |
Technical Indicators
Market Signals| Indicator | JYD | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 53.27 |
| Support Level | $3.96 | $7.76 |
| Resistance Level | $4.74 | $9.42 |
| Average True Range (ATR) | 0.47 | 1.35 |
| MACD | 0.04 | 0.17 |
| Stochastic Oscillator | 73.48 | 39.07 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).